#1 Clinical Trials Search in Europe

Utreglutide

A new clinical trial is underway to investigate the effectiveness and safety of Utreglutide (GL0034), a promising drug for adults with Type 2 diabetes. This Phase 2 study aims to explore how Utreglutide, administered once weekly, can help manage blood sugar levels in patients who haven’t responded well to metformin or lifestyle changes alone. The trial will assess various aspects of the drug’s performance, including its impact on body weight, blood glucose control, and other important health markers.

Table of Contents

What is Utreglutide?

Utreglutide, also known as GL0034, is a new medication being developed for the treatment of Type 2 diabetes mellitus. It belongs to a class of drugs called GLP-1 receptor agonists, which are analogs (similar versions) of a naturally occurring hormone in our body called glucagon-like peptide-1 (GLP-1)[1].

How Does Utreglutide Work?

As a GLP-1 receptor agonist, Utreglutide works by mimicking the effects of the GLP-1 hormone in your body. This hormone plays a crucial role in regulating blood sugar levels. Here’s how it helps:

  • It stimulates the release of insulin, a hormone that lowers blood sugar levels.
  • It reduces the production of glucagon, a hormone that raises blood sugar levels.
  • It slows down digestion, which can help control blood sugar levels after meals.
  • It may help reduce appetite and food intake, potentially aiding in weight loss.

Potential Benefits of Utreglutide

Based on the ongoing clinical trial, Utreglutide is being studied for its potential to offer several benefits for people with Type 2 diabetes[1]:

  • Improved blood sugar control: The primary goal is to help lower and stabilize blood sugar levels, as measured by glycated hemoglobin (HbA1c) and daily plasma glucose levels.
  • Weight loss: Many GLP-1 receptor agonists can help with weight loss, which is often beneficial for people with Type 2 diabetes.
  • Metabolic improvements: The study is looking at effects on various metabolic parameters, including insulin, C-peptide, and glucagon levels.
  • Cardiovascular benefits: The trial is assessing changes in lipid profiles, which could indicate potential cardiovascular benefits.

How is Utreglutide Administered?

Utreglutide is designed to be administered as a subcutaneous injection. This means it’s injected just under the skin, typically in areas like the abdomen, thigh, or upper arm. The medication is being developed in different concentrations (1 mg/ml, 3 mg/ml, and 4 mg/ml) and is intended to be given once weekly[1].

Current Clinical Trial

Utreglutide is currently being studied in a Phase 2 clinical trial. This trial aims to evaluate the safety and effectiveness of the drug in adults with Type 2 diabetes. Key aspects of the trial include[1]:

  • It’s a randomized, double-blind, placebo-controlled study, which means participants are randomly assigned to receive either Utreglutide or a placebo, and neither the participants nor the researchers know who is receiving which.
  • The treatment period is 16 weeks.
  • The study is testing different dosing schedules (titration algorithms) to find the most effective and well-tolerated approach.
  • The main focus is on safety and tolerability, particularly gastrointestinal side effects, which are common with this class of medications.

Who is Eligible for the Clinical Trial?

The trial has specific criteria for who can participate. Generally, eligible participants are[1]:

  • Adults aged 18 to 70 years
  • Diagnosed with Type 2 diabetes for at least 6 months
  • Have an HbA1c (a measure of average blood sugar) between 6.5% and 8.5%
  • Have a body mass index (BMI) between 28 and 50 kg/m²
  • Either managing their diabetes with diet and exercise alone or taking a stable dose of metformin (a common diabetes medication)

There are also several exclusion criteria, such as having Type 1 diabetes, being pregnant or breastfeeding, or having certain other medical conditions.

Safety Considerations

As with any medication, safety is a crucial consideration. The clinical trial is closely monitoring for side effects, particularly[1]:

  • Gastrointestinal effects: These are common with GLP-1 receptor agonists and may include nausea, vomiting, or diarrhea.
  • Changes in laboratory values: The study is monitoring various blood tests to ensure the medication is safe.
  • Other adverse events: Any unexpected side effects will be carefully tracked and evaluated.

It’s important to note that Utreglutide is still in the testing phase, and more research is needed to fully understand its benefits and potential risks. If you have Type 2 diabetes and are interested in new treatment options, always consult with your healthcare provider to discuss what might be best for you.

Aspect Details
Drug Name Utreglutide (GL0034)
Trial Phase Phase 2
Target Condition Type 2 diabetes mellitus
Administration Once weekly subcutaneous injection
Treatment Duration 16 weeks
Main Objectives Safety, tolerability, effects on body weight and blood glucose control
Key Eligibility Criteria Adults 18-70 years, T2DM diagnosis for at least 6 months, specific HbA1c and BMI ranges
Primary Endpoints Incidence and severity of gastrointestinal adverse events
Secondary Endpoints Changes in HbA1c, plasma glucose, body weight, waist circumference, lipid profile, and pharmacokinetics

FAQ

  • What is Utreglutide (GL0034)? Utreglutide, also known as GL0034, is a new drug being tested for Type 2 diabetes treatment. It's similar to a hormone in your body called GLP-1, which helps control blood sugar levels.
  • Who can participate in this clinical trial? The trial is open to adults aged 18-70 with Type 2 diabetes diagnosed at least 6 months ago. Participants should have specific blood sugar levels and body mass index, and be managing their condition with diet and exercise or a stable dose of metformin.
  • How is Utreglutide given to patients in the trial? Utreglutide is given as a solution for injection under the skin (subcutaneous injection) once a week for 16 weeks during the trial.
  • What will the trial measure? The trial will primarily look at the safety and side effects of Utreglutide, especially those related to the digestive system. It will also measure changes in blood sugar control, body weight, waist size, and other health indicators like cholesterol levels.
  • Are there any reasons someone might not be able to join the trial? Yes, people with Type 1 diabetes, pregnant or nursing women, those allergic to similar drugs, or individuals who have used certain diabetes medications recently are not eligible. The trial also excludes people with a history of pancreatitis or very high triglyceride levels.

Ongoing Clinical Trials on Utreglutide

  • Study on the Safety and Effectiveness of Utreglutide (GL0034) for Adults with Type 2 Diabetes Not Well Managed with Metformin or Lifestyle Changes

    Not recruiting

    1
    Investigated drugs:
    Germany

Glossary

  • Type 2 diabetes mellitus (T2DM): A chronic condition that affects the way your body processes blood sugar (glucose). It occurs when your body becomes resistant to insulin or doesn't make enough insulin.
  • Glycated hemoglobin (HbA1c): A blood test that shows your average blood sugar levels over the past 2-3 months. It's used to diagnose diabetes and monitor how well you're managing your condition.
  • Metformin: A common medication used to treat Type 2 diabetes by improving the way your body handles insulin and reducing the amount of sugar your liver releases.
  • Body mass index (BMI): A measure that uses your height and weight to work out if your weight is healthy. It's calculated by dividing your weight in kilograms by your height in meters squared.
  • GLP-1 receptor agonist: A type of medication that mimics a hormone called glucagon-like peptide-1, which helps control blood sugar levels and can assist with weight loss.
  • Subcutaneous injection: A method of giving medication by injecting it under the skin, rather than into a vein or muscle.
  • Pancreatitis: Inflammation of the pancreas, an organ that produces enzymes to help digest food and hormones to regulate blood sugar.
  • Triglycerides: A type of fat found in your blood. High levels can increase your risk of heart disease.
  • Lipid profile: A blood test that measures different types of fats in your blood, including cholesterol and triglycerides.
  • Pharmacokinetics: The study of how a drug moves through your body, including how it's absorbed, distributed, metabolized, and eliminated.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-utreglutide-gl0034-for-adults-with-type-2-diabetes-not-well-managed-with-metformin-or-lifestyle-changes/